EC approves Actavis' Xydalba for ABSSSIs

The European Commission approved an MAA for Xydalba dalbavancin from Actavis plc (NYSE:ACT) to treat acute bacterial skin and skin structure infections (ABSSSIs) in adults. The approval triggers a $1 contingent value right (CVR) payment to shareholders of Durata Therapeutics Inc., which Actavis acquired last year (see BioCentury Extra, Oct. 6, 2014).

Actavis markets the second-generation glycopeptide antibiotic in the U.S. as Dalvance to treat ABSSSIs caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). ...